Dr David L Smith, MD | |
599 W State St, Ste 200, Doylestown, PA 18901-2567 | |
(215) 345-6050 | |
(215) 345-6568 |
Full Name | Dr David L Smith |
---|---|
Gender | Male |
Speciality | Cardiovascular Disease (cardiology) |
Experience | 40 Years |
Location | 599 W State St, Doylestown, Pennsylvania |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1659370104 | NPI | - | NPPES |
110047146 | Other | PA | MEDICARE RAILROAD |
0012862990001 | Medicaid | PA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RC0000X | Internal Medicine - Cardiovascular Disease | MD034865E (Pennsylvania) | Primary |
174400000X | Specialist | MD034865E (Pennsylvania) | Secondary |
Facility Name | Location | Facility Type |
---|---|---|
Doylestown Hospital | Doylestown, PA | Hospital |
Grand View Hospital | Sellersville, PA | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Via Affiliates | 1759295512 | 182 |
News Archive
Even with the advent of vaccines, strategies for rapid and affordable testing for COVID-19 are still paramount.
Researchers at the Baylor Institute for Immunology Research have discovered that the neutrophils of systemic lupus erythematosus (SLE) patients release oxidized DNA from their mitochondria that can stimulate an unwanted immune response.
Tuberculosis is a highly contagious infectious disease that is typically spread through aerosols and mainly affects the lungs. According to the World Health Organization (WHO), an estimated 1.7 million people die from such an infection worldwide every year.
Stealth Peptides Incorporated, a privately held biopharmaceutical company developing innovative therapies for cardiovascular disease and its complications, announced today that the first patient was enrolled in its multinational Phase II clinical study with Bendavia focused on ischemia reperfusion and microvascular injuries for patients experiencing acute ST-segment elevation myocardial infarction.
› Verified 5 days ago
Entity Name | Via Affiliates |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1003446261 PECOS PAC ID: 1759295512 Enrollment ID: O20031117000104 |
News Archive
Even with the advent of vaccines, strategies for rapid and affordable testing for COVID-19 are still paramount.
Researchers at the Baylor Institute for Immunology Research have discovered that the neutrophils of systemic lupus erythematosus (SLE) patients release oxidized DNA from their mitochondria that can stimulate an unwanted immune response.
Tuberculosis is a highly contagious infectious disease that is typically spread through aerosols and mainly affects the lungs. According to the World Health Organization (WHO), an estimated 1.7 million people die from such an infection worldwide every year.
Stealth Peptides Incorporated, a privately held biopharmaceutical company developing innovative therapies for cardiovascular disease and its complications, announced today that the first patient was enrolled in its multinational Phase II clinical study with Bendavia focused on ischemia reperfusion and microvascular injuries for patients experiencing acute ST-segment elevation myocardial infarction.
› Verified 5 days ago
Mailing Address | Practice Location Address |
---|---|
Dr David L Smith, MD Po Box 829641, Philadelphia, PA 19182-9641 Ph: (267) 370-5295 | Dr David L Smith, MD 599 W State St, Ste 200, Doylestown, PA 18901-2567 Ph: (215) 345-6050 |
News Archive
Even with the advent of vaccines, strategies for rapid and affordable testing for COVID-19 are still paramount.
Researchers at the Baylor Institute for Immunology Research have discovered that the neutrophils of systemic lupus erythematosus (SLE) patients release oxidized DNA from their mitochondria that can stimulate an unwanted immune response.
Tuberculosis is a highly contagious infectious disease that is typically spread through aerosols and mainly affects the lungs. According to the World Health Organization (WHO), an estimated 1.7 million people die from such an infection worldwide every year.
Stealth Peptides Incorporated, a privately held biopharmaceutical company developing innovative therapies for cardiovascular disease and its complications, announced today that the first patient was enrolled in its multinational Phase II clinical study with Bendavia focused on ischemia reperfusion and microvascular injuries for patients experiencing acute ST-segment elevation myocardial infarction.
› Verified 5 days ago
Andrew E Krick, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 310 Farm Lane, Doylestown, PA 18901 Phone: 215-348-3990 Fax: 215-348-7705 | |
Sherilyn Lisa Tittermary Mccollum, D.O. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1456 Ferry Road, Suite 403, Doylestown, PA 18901 Phone: 267-483-8094 Fax: 267-483-8312 | |
Dr. George Wiemann, M.D, FACC Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 315 W State St, Doylestown, PA 18901 Phone: 215-345-1900 Fax: 215-345-4579 | |
Marvin Ralph Gordon, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 4740 Dickinson Way, Doylestown, PA 18902 Phone: 215-794-2528 Fax: 267-544-0105 | |
Christopher P Hermann, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 301s Main St, Ste 2w, Doylestown, PA 18901 Phone: 215-348-4800 Fax: 215-348-4350 | |
Mr. Les A Szekely, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2003 Lower State Rd Unit 110, Doylestown, PA 18901 Phone: 215-348-1310 Fax: 215-348-8615 | |
Venu Pasricha, Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 595 W State St, Doylestown, PA 18901 Phone: 215-345-2885 Fax: 215-345-2552 |